APA (7th ed.) Citation

Peters, S., Tang, H., Shafiq, T., Karim, S., Khan, S., Trivedi, S., . . . Madhusudan, S. (2023). A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer. Clinical Oncology, 35(6), e419. https://doi.org/10.1016/j.clon.2023.02.038

Chicago Style (17th ed.) Citation

Peters, S., et al. "A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer." Clinical Oncology 35, no. 6 (2023): e419. https://doi.org/10.1016/j.clon.2023.02.038.

MLA (9th ed.) Citation

Peters, S., et al. "A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer." Clinical Oncology, vol. 35, no. 6, 2023, p. e419, https://doi.org/10.1016/j.clon.2023.02.038.